Genomic Evidence for a Case of Reinfection with SARS-CoV-2

Tillett, Richard L.; Sevinsky, Joel; Hartley, Philip; Kerwin, Heather; Crawford, N. F.; Gorzalski, Andrew; Laverdure, Christopher; Verma, Subhash C.; Rossetto, Cyprian C.; Jackson, David J.; Farrell, Megan J.; Hooser, Stephanie Van; Pandori, Mark

doi:10.2139/ssrn.3680955

Cited by 89 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although a rare event, several cases evidenced by a phylogenetically distinct strain of SARS COV-2 have now been demonstrated. [6][7][8] These reinfections have been shown to occur several months after the 1st episode. Knowing that our population consisted of 27% of health care workers, the hypothesis of a reinfection cannot be excluded.…”

Section: Discussionmentioning

confidence: 99%

Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study

Salmon‐Céron

Slama

Broucker

et al. 2021

Journal of Infection

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study

Salmon‐Céron

Slama

Broucker

et al. 2021

Journal of Infection

View full text Add to dashboard Cite

“…Two studies involving re-infection of non human primates with SARS-CoV-2 after a primary infection showed that the animals were resistant to re-infection with no evidence of enhanced disease (31,32). Recently, one patient in the United States was reported to have a more severe clinical course when infected with SARS-CoV-2 a second time (92). While it is difficult to interpret data from a single case report, it will be important to monitor the frequency of repeat infections with SARS-CoV-2 and the clinical course of disease to determine if this finding is relevant more broadly.…”

Section: Does Immune Enhancement Of Disease Occur In Human Coronavirumentioning

confidence: 99%

Prospects for a safe COVID-19 vaccine

et al. 2020

View full text Add to dashboard Cite

Rapid development of an efficacious vaccine against the viral pathogen SARS-CoV-2, the cause of the coronavirus disease-2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and post-licensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, following vaccination.

show abstract

“…Our hypothesis that sufficient postexposure protection can be surmised reliably with SARS-CoV-2 further leans on (1) prior evidence of mostly strain-specific immunity with other coronaviruses (22,23,29); (2) a complete lack of reliable evidence regarding any COVID-19 reinfections so far (20,30) [with a few notable exceptions among >30 million cases worldwide as of mid-September 2020 (39,40)]; and (3) on the fact that natural infection produces lasting immunity, which varies in duration based on the type of virus and its strain (27).…”

mentioning

confidence: 88%